RxDoctor Payments Data

Galal Gargodhi, MD

Pain Medicine · Duluth, GANPI 1245594985

Payments from drug & device makers

What this record shows

The money is spread across several categories — food and beverage (54.7%), travel and lodging and education — rather than concentrated in one kind of arrangement. 28 manufacturers reported payments, led by Medtronic at 32.4% of the total. Reporting peaked in 2019 at $4,184 and has fallen 85.0% since, to $628 in 2025. Among pain medicine clinicians in GA with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$11,265in general payments, 2019–2025

Across 193 payments — averaging $58.37 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Medtronic$4K
  • Abbott$2K
  • Vertiflex, Inc.$2K
  • Boston Scientific$787
  • Nevro Corp.$296
  • AbbVie$246
  • plus $1K from 22 others

What the payments were for

  • Travel & lodging$4,82143%
  • Food & beverage$6,15755%
  • Education$2873%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$11,265 in reported general payments places this provider in the 90th percentile of 203 pain medicine providers in Georgia.

See all pain medicine providers in Georgia

Medicare billing

Part B allowed, 2024
$57,960
Medicare patients
71
Services billed
4,526

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Buprenorphine Hcl15$1,769
Oxycodone-AcetaminophenOxycodone Hcl/Acetaminophen43$1,745
Hydrocodone-AcetaminophenHydrocodone/Acetaminophen51$828
Gabapentin69$562
Oxycodone Hcl24$446
Tizanidine Hcl46$420
Duloxetine Hcl21$350
Morphine Sulfate12$341
Meloxicam71$171
Methocarbamol15$138
Pregabalin18$119
Tramadol Hcl12$81

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Hikma Pharmaceuticals USABuprenorphine Hcl, Morphine Sulfate$13$2,11027 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 203 pain medicine providers in Georgia.

Other pain medicine in Duluth

See the full list for Georgia

Where these figures come from

Is this you, or does something look wrong? →